drugset / Trial / NCT06504043
A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants
RandomizedSequentialTriple-blindTreatment
Summary
This is a single-center, randomized, double-blind, placebo-controlled, single HST101 SC dose cohort study to evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Chinese Participants with Elevated LDL-C Levels.
Timeline
- Start
- 2024-09-17
- Primary completion
- 2025-01-08
- Completion
- 2025-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | lerodalcibep | Protein / enzyme biologic | 150 mg | Subcutaneous |
| Subject | lerodalcibep | Protein / enzyme biologic | 300 mg | Subcutaneous |